Fifth Circuit Stays FDA Mifepristone Rule, Reimposing In-Person Pickup Nationwide
Updated
Updated · adamunikowsky.substack.com · May 11
Fifth Circuit Stays FDA Mifepristone Rule, Reimposing In-Person Pickup Nationwide
9 articles · Updated · adamunikowsky.substack.com · May 11
A May 1 Fifth Circuit order blocked the FDA’s 2023 mifepristone REMS change, which had allowed certified pharmacies and mail dispensing instead of in-person pickup from providers.
The ruling came in Louisiana v. FDA, where Louisiana argued the looser rule undermined its abortion restrictions and imposed Medicaid costs tied to two 2025 emergency cases totaling about $92,000.
The Supreme Court has temporarily frozen the Fifth Circuit order, so pharmacy and mail access remains in place for now while it decides whether to keep that block during the appeal.
The fight centers on whether Louisiana has standing to challenge a nationwide FDA safety rule and whether the agency acted lawfully after years of review dating back to its 2021 decision to drop the in-person requirement.
Can one state’s financial claim dictate nationwide access to a long-approved medication?
If courts can override FDA science on one drug, what prevents challenges to vaccines or other common medications?
Supreme Court Set to Decide Fate of Mail-Order Abortion Pills: The Legal Battle Over Mifepristone Access in 2026
Overview
As of May 11, 2026, the Supreme Court has temporarily allowed continued access to the abortion pill by mail, but only for a few days, signaling an imminent and decisive ruling on its future availability. This follows the FDA’s 2023 update to its REMS program, which expanded access by permitting mifepristone to be dispensed by mail. The change sparked a major legal challenge, questioning both the FDA’s authority and the balance between federal and state power over abortion. The upcoming Supreme Court decision will determine whether expanded mail access remains or stricter, in-person requirements return, shaping reproductive healthcare nationwide.